Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
GEF-H1 activator
DRUG CLASS:
GEF-H1 activator
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
BPI 2358 (2)
BPI 2358 (2)
›
Associations
(2)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Pembrolizumab in Combination with Plinabulin and Docetaxel for Metastatic NSCLC After ICIs (KeyPemls-004) (NCT05599789)
Phase 2
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Active, not recruiting
Phase 2
Peking Union Medical College Hospital
Active, not recruiting
Last update posted :
02/18/2025
Initiation :
02/01/2023
Primary completion :
01/21/2025
Completion :
12/31/2025
EGFR • ALK • ROS1
|
Keytruda (pembrolizumab) • docetaxel • plinabulin (BPI 2358)
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/14/2024
Initiation :
04/14/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) (NCT05130827)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
08/03/2023
Initiation :
12/21/2021
Primary completion :
11/01/2025
Completion :
11/01/2025
CD34
|
plinabulin (BPI 2358) • Neulasta (pegfilgrastim)
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) (NCT02504489)
Phase 3
BeyondSpring Pharmaceuticals Inc.
BeyondSpring Pharmaceuticals Inc.
Completed
Phase 3
BeyondSpring Pharmaceuticals Inc.
Completed
Last update posted :
09/10/2022
Initiation :
12/01/2015
Primary completion :
03/23/2021
Completion :
05/23/2021
EGFR • ALK
|
EGFR L858R • EGFR exon 19 deletion • ALK rearrangement
|
docetaxel • dexamethasone • plinabulin (BPI 2358)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login